{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:01:34Z","timestamp":1787166094216,"version":"build-2736575974"},"reference-count":19,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:p>Cystinuria is an autosomal recessive disorder characterized by excessive urinary excretion of cystine, resulting in recurrent cystine kidney stones, often presenting in childhood. Current treatment options for cystinuria include dietary and\/or fluid measures and potassium citrate to reduce cystine excretion and\/or increase solubility. Tiopronin and D-penicillamine are used in refractory cases to bind cystine in urine, albeit with serious side effects. A recent study revealed efficacy of nutritional supplement \u03b1-lipoic acid (ALA) treatment in preventing kidney stones in a mouse model of cystinuria. Here, we report 2 pediatric patients (6 and 15 years old) with cystinuria who received regular doses of ALA in addition to conventional therapy with potassium citrate. Both patients tolerated ALA without any adverse effects and had reduced frequency of symptomatic and asymptomatic kidney stones with disappearance of existing kidney stones in 1 patient after 2 months of ALA therapy. ALA treatment markedly improved laboratory markers of cystine solubility in urine with increased cystine capacity (\u2212223 to \u22121 mg\/L in patient 1 and +140 to +272 mg\/L in patient 2) and decreased cystine supersaturation (1.7 to 0.88 in patient 1 and 0.64 to 0.48 in patient 2) without any changes in cystine excretion or urine pH. Our findings suggest that ALA improves solubility of cystine in urine and prevents stone formation in patients with cystinuria who do not respond to diet and citrate therapy.<\/jats:p>","DOI":"10.1542\/peds.2019-2951","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T08:25:13Z","timestamp":1585902313000},"source":"Crossref","is-referenced-by-count":15,"title":["\u03b1-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases"],"prefix":"10.1542","volume":"145","author":[{"given":"Onur","family":"Cil","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Perwad","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"issue":"1","key":"2021121013091343500_B1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00240-018-1101-7","article-title":"Cystinuria: genetic aspects, mouse models, and a new approach to therapy","volume":"47","author":"Sahota","year":"2019","journal-title":"Urolithiasis"},{"issue":"6","key":"2021121013091343500_B2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11934-019-0891-7","article-title":"Outcomes and long-term follow-up of patients with cystine stones: a systematic review","volume":"20","author":"Moore","year":"2019","journal-title":"Curr Urol Rep"},{"issue":"8","key":"2021121013091343500_B3","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2215\/CJN.10651110","article-title":"Chronic kidney disease in kidney stone formers","volume":"6","author":"Rule","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2021121013091343500_B4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(05)64824-0","article-title":"The impact of cystinuria on renal function","volume":"168","author":"Assimos","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"2021121013091343500_B5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0022-5347(05)67633-1","article-title":"Medical treatment of cystinuria: critical reappraisal of long-term results","volume":"163","author":"Barbey","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"2021121013091343500_B6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7257\/1053-816X.2017.37.2.81","article-title":"Early recognition and management of rare kidney stone disorders","volume":"37","author":"Goldstein","year":"2017","journal-title":"Urol Nurs"},{"issue":"10","key":"2021121013091343500_B7","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2215\/CJN.11201016","article-title":"Effectiveness of treatment modalities on kidney stone recurrence","volume":"12","author":"Zisman","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2021121013091343500_B8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1900\/RDS.2009.6.230","article-title":"Alpha-lipoic acid and diabetic neuropathy","volume":"6","author":"Vallianou","year":"2009","journal-title":"Rev Diabet Stud"},{"issue":"3","key":"2021121013091343500_B9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.4280","article-title":"\u03b1-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria","volume":"23","author":"Zee","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"2021121013091343500_B10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yrtph.2006.06.004","article-title":"Safety evaluation of alpha-lipoic acid (ALA)","volume":"46","author":"Cremer","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"2021121013091343500_B11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yrtph.2006.06.003","article-title":"Long-term safety of alpha-lipoic acid (ALA) consumption: a 2-year study","volume":"46","author":"Cremer","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"issue":"11","key":"2021121013091343500_B12","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"issue":"2","key":"2021121013091343500_B13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.juro.2014.05.006","article-title":"Medical management of kidney stones: AUA guideline","volume":"192","author":"Pearle","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"2021121013091343500_B14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5347(05)67011-5","article-title":"Clinical use of cystine supersaturation measurements","volume":"164","author":"Nakagawa","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"2021121013091343500_B15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-5347(05)66044-2","article-title":"Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs","volume":"166","author":"Coe","year":"2001","journal-title":"J Urol"},{"issue":"6","key":"2021121013091343500_B16","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.ki.5000104","article-title":"Urinary cystine excretion and capacity in patients with cystinuria","volume":"69","author":"Goldfarb","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"2021121013091343500_B17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semnephrol.2008.01.001","article-title":"Evaluation of the kidney stone patient","volume":"28","author":"Asplin","year":"2008","journal-title":"Semin Nephrol"},{"issue":"6","key":"2021121013091343500_B18","doi-asserted-by":"crossref","first-page":"632.e1","DOI":"10.1016\/j.jpurol.2017.06.014","article-title":"Analyte variations in consecutive 24-hour urine collections in children","volume":"13","author":"Ellison","year":"2017","journal-title":"J Pediatr Urol"},{"issue":"10","key":"2021121013091343500_B19","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1097\/01.ASN.0000029586.17680.E5","article-title":"Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification","volume":"13","author":"Dello Strologo","year":"2002","journal-title":"J Am Soc Nephrol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-2951\/1079640\/peds_20192951.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-2951\/1079640\/peds_20192951.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T20:51:49Z","timestamp":1639169509000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/145\/5\/e20192951\/36811\/Lipoic-Acid-ALA-Improves-Cystine-Solubility-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2019-2951","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"article-number":"e20192951"}}